To include your compound in the COVID-19 Resource Center, submit it here.

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides.

Ervaxx Ltd. will fund research, conducted in the lab of SAB member Andrew Sewell, to discover and characterize

Read the full 427 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE